Ischemic stroke remains one of the leading causes of mortality and long-term disability worldwide, and existing treatments are bounded by narrow therapeutic windows and low efficacy. Inert gases, particularly argon, have recently emerged as promising neuroprotectors capable of modulating the cellular response to ischemia. However, the analysis of their effects at the systemic, tissue, and cellular levels remains incomplete. The aim of the study was to provide an comprehensive assessment of the neuroprotective properties of argon in vitro and in vivo using the focal cerebral ischemia model in rats . Materials and methods. A two-stage experimental study was conducted, combining in vivo and in vitro approaches. In vivo, focal ischemic stroke was induced in rats using a model of photochemically initiated thrombosis. The animals with induced stroke were divided into two groups based on inhalation mixture composed of N₂ 70% / O₂ 30% (comparison group I + iN₂, n = 10) and Ar 70% / O₂ 30% (main group I + iAr, n = 10). Additionally, 3 groups were included in the experiment: sham-operated animals (SO, n = 6), subjected to sham surgery without stroke induction, and 2 groups of intact animals receiving three inhalations of studied gas mixtures: Int. + iN₂ , n = 7; Int. + iAr, n = 5. Neurological outcomes were studied in a longitudinal mode, followed by a quantitative assessment of the infarction volume based on MRI data, histological and immunohistochemical analyses (GFAP, Iba-1, S100b, caspase-3, von Willebrand factor, etc.), and quantification of marker proteins involved in the regulation of signaling pathways (Akt/GSK-3, Nrf2, NFκB, IL-1α, IL-6, caspase-3) using western blotting. In vitro cultures of neuronal (SH-SY5Y), glial (C6), and endothelial (Ea.Hy926) cells were incubated in an argon-oxygen medium for 24 hours. Functional studies of cultures included assessment of mitochondrial transmembrane potential and lysosomal activity using confocal microscopy. Results. In an in vivo experiment, argon significantly reduced the volume of damage according to MRI data (I + iN2 21.5 ± 5.9 mm³ vs I + iAr 12.5 ± 4.3 mm³, p = 0.0078), improved neurological recovery (I + N₂ and I + iAr group: on the 3[rd] (7.5 (4.2; 10.2) vs 10.0 (10.0; 12.0), p = 0.0015), 7[th] (8.0 (6.7; 9.2) vs 10.0 (9.0; 12.2), p = 0.038) and 14[th] days of the study (4.5 (2.7; 7.2) vs 12.0 (10.7; 12.2), p = 0.0008), It preserved significant neuronal density in the penumbra ( p = 0.001), and downregulated astroglia and microglia activation. In addition to a significant decrease in caspase-3 expression ( p = 0.002) and modulation of pro-inflammatory cytokines (Ila was significantly lower in the I + iAr group, p = 0.002), there was an apparent activation of cytoprotective signaling pathways (Akt ( p = 0.006) and Nrf2 ( p = 0.019)). In vitro , argon exposure increased the proportion of high-potential mitochondria in neuronal ( p = 0.01) and glial cells ( p < 0.0001), and significantly stimulated lysosomal activity in endothelial cells ( p = 0.0006). Conclusion. This comprehensive study demonstrates that argon has a pronounced neuroprotective effect in a model of ischemic brain damage, manifesting by reduction of ischemic lesion volume, improvement in neurological status, and modulation of key molecular and cellular mechanisms of damage. The results demonstrate that argon activates protective mechanisms both in vivo and vitro. Therefore, argon can be considered as a promising and safe candidate for further preclinical and clinical studies in the field of neuroprotective therapy.